Fintel reports that on December 13, 2023, Citigroup initiated coverage of Neurocrine Biosciences (NASDAQ:NBIX) with Neutral recommendation
Analysis Price Forecast Suggests 12.81% Up
As of November 27, 2023, the average one-year price target for Neurocrine Biosciences is 137.23. The forecasts range from a low of 101.00 to a high of $178.50. The average price target represents a 12.81% increase from its last reported close price of 121.65.
See our leaderboard of companies with the largest price target.
The projected annual revenue for Neurocrine Biosciences is 1,807MM, an increase of 1.29%. The projected annual non-GAAP EPS is 3.76.
What is the Basic Sense?
There are 1119 funds or institutions reporting positions in Neurocrine Biosciences. This is an increase of 94 owner(s) or 9.17% in the last quarter. Average portfolio weight of all funds dedicated to NBIX is 0.29%, an increase of 8.50%. Total shares owned by institutions increased in the last three months by 2.51% to 105,463K shares. NBIX’s put/call ratio is 1.20, indicating a bearish outlook.
What Are Other Shareholders Doing?
IJH – iShares Core S&P Mid-Cap ETF holds 3,052K shares representing 3.11% ownership of the company. In its previous filing, the company reported owning 2,960K shares, representing an increase of 3.01%. The company increased its portfolio allocation in NBIX by 20.55% during the last quarter.
VTSMX – Vanguard Total Stock Market Index Fund Investor Shares holds 3,035K shares representing 3.09% ownership of the company. In its previous filing, the company reported owning 3,016K shares, representing an increase of 0.63%. The company increased its portfolio allocation in NBIX by 24.61% during the last quarter.
Bellevue Group holds 2,584K shares representing 2.63% ownership of the company. In its previous filing, the company reported owning 2,613K shares, representing decline of 1.13%. The company increased its portfolio allocation in NBIX by 33.24% during the last quarter.
Point72 Asset Management holds 2,578K shares representing 2.62% ownership of the company. In its previous filing, the company reported owning 111K shares, representing an increase of 95.68%. The company increased its portfolio allocation in NBIX by 2,609.82% during the last quarter.
NAESX – Vanguard Small-Cap Index Fund Investor Shares holds 2,513K shares representing 2.56% ownership of the company. In its previous filing, the company reported owning 2,519K shares, representing decline of 0.23%. The company increased its portfolio allocation in NBIX by 24.80% during the last quarter.
Neurocrine Biosciences Background Information
(This description is provided by the company.)
Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company dedicated to discovering, developing and delivering life-changing treatments for people with serious, challenging and undertreated neurological, endocrine and psychiatric disorders. The company’s diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson’s disease, endometriosis*, uterine fibroids* and clinical programs in multiple therapeutic areas. For nearly three decades, Neurocrine Biosciences has specialized in targeting and disrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems.
Fintel is one of the most comprehensive investment research platforms available for individual investors, traders, financial advisors and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fundamental sentiment, option sentiment, insider trading, option flow, unusual options trades and much more. Additionally, our exclusive stock options are powered by advanced, back-tested quantitative models for enhanced returns.
Click to Learn More
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.